Table 1B.

Studies included in review.

StudyZeitz et al12Barthel et al4Minden et al8Toussirot et al7
Publish yr2015201520122012
Study designObservationalPros. cohortObservational
SexMFMFFFFFFFNSNSMFM
Age at IBD onset, yrs198.216.411.411.817.212.211.71210.2> 21> 21118317
Underlying diseaseERA JIAPoly RF-JIAERA JIAOligo JIAPoly RF-JIAERA JIAPoly RF-JIAOligo JIAOligo JIARF-JIAPoly JIAERA JIAERA JIARAERA JIA
Age at rheumatic disease onset, yrs72.712.49.63.11026.74.15.4NSNS107111
Duration of ETN treatment, yrs3NSNSNSNSNSNSNSNSNSNSNS0.80.81.5
Time from disease diagnosis to ETN start, yrs93.83.30.57.15.59.82.36.33.5NSNS0.311.34.5
Time from ETN to IBD, yrs3NSNSNSNSNSNSNSNSNSNSNS0.80.81.5
CD/UCCDCDCDCDUCUCCDCDUCCDIDIDCDCDCD
BiopsyYYYYYYYYYYNSNSYYY
Concomitant treatmentIFX, PSLPSLMTX, PSL, NSAIDNonePSL, NSAIDSSZ, NSAIDNoneNSAIDLEFNoneNSNSNSNSNS
Decrease in IBD symptomsIBD improvedIBD improvedIBD improvedIBD persistedIBD improvedNSIBD persistedIBD improvedIBD improvedIBD persistedNSNSNSNSNS
IBD treatment afterNSSSZETN cont + MTX, PSL, NSAIDMTX, PSL SSZMTX, IFX, SSZSSZADA, AZA, PSLADA, SSZ, PSLMSZ, ADA, PSLADA, PSL, MSZNSNSIFXADAADA
IBD progression: penetrating, stricturing, inflammatoryFistulatingInflammatoryNSInflammatoryInflammatoryInflammatoryInflammatoryInflammatoryInflammatoryInflammatoryNSNSNSNSNS
  • IBD: inflammatory bowel disease; ETN: etanercept; CD: Crohn disease; UC: ulcerative colitis; pros. cohort: prospective cohort; NS: not specified; ERA: enthesitis-related arthritis; JIA: juvenile idiopathic arthritis; poly: polyarticular; RF: rheumatoid factor; oligo: oligoarticular; RA: rheumatoid arthritis; ID: undifferentiated IBD; IFX: infliximab; PSL: prednisone; MTX: methotrexate; NSAID: nonsteroidal antiinflammatory drugs; SSZ: sulfasalazine; LEF: leflunomide; ETN cont.: ETN continuous; ADA: adalimumab; AZA: azathioprine; MSZ: mesalazine.